Catalina Health addresses medication nonadherence with Health Consumer Journey
ST PETERSBURG, Fla. — A division of Catalina Marketing has introduced a healthcare solution designed to drive medication adherence and create healthier outcomes for patients.
Catalina Health said its Health Consumer Journey turns in-depth insights — gathered from its privacy protected, proprietary pharmacy databases — into personalized patient education that is clinically and emotionally relevant, and delivers it to health consumers where they need it most — right at the pharmacy point-of-care, the company said.
“You can’t incite change unless you know what’s preventing adherence on an individual basis,” Catalina Health president Renee Selman said. “The Health Consumer Journey is reinventing the way we help drive adherence by understanding each patient is on a different health journey, examining their unique emotional drivers, and crafting meaningful messaging that resonates and motivates the individual health consumer.”
Studies further underscore importance of convenient care industry
WHAT IT MEANS AND WHY IT’S IMPORTANT — The recently released report by Kalorama Information indicating that retail-based health clinics are a viable business for retailers — if managed correctly — further underscores the importance of the convenient care industry, and comes just as a separate study highlighted the value of employer-based on-site health clinics.
(THE NEWS: Study: Retail-based clinics a viable business for Walmart, other retailers, if managed correctly. For the full story, click here)
Kalorama’s study suggested that retail-based health clinics are a viable business for retailers given they are managed correctly. Pointing to the success of those clinics within pharmacies, such as MinuteClinic and Take Care Clinics, Kalorama indicated that such retailers as Walmart would benefit from tying the clinics into the store versus keeping them as independent entities outside of the main traffic zone.
The study comes as news swirls that Walmart is looking to form strategic partnerships to expand the service offering within its 140 clinics nationwide.
Meanwhile, a separate study emerged examining the benefits of on-site health clinics.
The study, conducted by the Government Finance Officers Association with a grant from Colonial Life, found that employer-based on-site health clinics not only help employees lead healthier lives given the convenient and affordable healthcare services they provide but also the return on investment is significant — $1.60 to $4 saved for every dollar invested. That is significant and clearly it’s a win-win situation for both the employer and the employee.
Given the rising healthcare costs and the ongoing physician shortage plaguing an already overloaded healthcare system, studies such as these are important as they shed additional light on the valuable role that retail-based and employer-based health clinics play in helping Americans lead healthier lives.
Genzyme announces phase-3 results of Lemtrada in patients with relapsing MS
CAMBRIDGE, Mass. — A late-stage clinical trial of a drug under development as a treatment for multiple sclerosis has shown "successful" results.
Genzyme, acquired earlier this year by French drug maker Sanofi, announced results of the phase-3 "CARE-MS II" trial of Lemtrada (alemtuzumab), saying the drug "significantly reduced" worsening of disability and relapse in patients with MS, compared with Rebif (interferon beta-1a), made by Pfizer and German drug maker Merck KGaA, a separate company from U.S.-based Merck.
"CARE-MS II represents the culmination of many years of clinical and laboratory research aimed at demonstrating the potential for alemtuzumab as a highly effective treatment for MS and understanding mechanisms involved in the complex natural history of the disease," University of Cambridge clinical neuroscience professor Alastair Compston said on behalf of Genzyme. "Taken together, the phase-2 and phase-3 clinical trial data illustrate the promise that alemtuzumab holds as a transformative treatment for people with relapsing MS."